In partnership with the Universidad Peruana Cayetano Heredia (UPCH) and the Instituto de Investigacion Nutricional (IIN), the Vanderbilt Institute for Global Health (VIGH) has received $1.2 million for a five-year training grant funded by the Fogarty International Center to establish the Peru-Vanderbilt Prevention through Vaccination Training program.
Vanderbilt’s participation in vaccine effectiveness research continues to grow, with the Medical Center playing critical roles in several networks focused on surveillance of vaccine-preventable respiratory diseases.
VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.
It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.
In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.
Accessibility Tools